Forecasting The Future: 4 Analyst Projections For ADMA Biologics

Analysts' ratings for ADMA Biologics ADMA over the last quarter vary from bullish to bearish, as provided by 4 analysts.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

Analysts have set 12-month price targets for ADMA Biologics, revealing an average target of $6.75, a high estimate of $9.00, and a low estimate of $6.00. This upward trend is evident, with the current average reflecting a 12.5% increase from the previous average price target of $6.00.

Exploring Analyst Ratings: An In-Depth Overview

The perception of ADMA Biologics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ADMA Biologics. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of ADMA Biologics compared to the broader market.
• Price Targets: Analysts navigate through adjustments in price targets, providing estimates for ADMA Biologics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into ADMA Biologics's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on ADMA Biologics analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Unveiling the Story Behind ADMA Biologics

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services.

Financial Milestones: ADMA Biologics's Journey

Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.

Revenue Growth: ADMA Biologics's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2023, the company achieved a revenue growth rate of approximately 63.72%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: ADMA Biologics's net margin is impressive, surpassing industry averages. With a net margin of 3.81%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): ADMA Biologics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.72%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): ADMA Biologics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.74% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: ADMA Biologics's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.01, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.

How Are Analyst Ratings Determined?

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga's automated content engine and reviewed by an editor.